Science Stories
As we deepen our commitment to oncology, we’re focused on bringing forward meaningful innovation for patients, especially those facing rare and aggressive cancers like H3 K27M-mutant diffuse midline glioma. With the FDA approval of the first treatment for this cancer, there is new hope for patients and families who are navigating this life-threatening disease.
Dravet syndrome is a rare, severe, lifelong form of treatment-resistant epilepsy that typically begins in the first year of life.
The onset of cardiovascular events and risk factors is high among those living with narcolepsy, even among patients who do not have a history of these cardiovascular conditions. Learn more about the key findings of the CV-BOND study, recently presented by Rami H. Ben-Joseph, Ph.D., head of big data real world evidence at Actelion.
Epilepsy is a neurological disorder characterized by the occurrence of at least two unprovoked seizures occurring more than 24 hours apart or by one unprovoked seizure with a high probability of further seizures.